Mineralocorticoid resistance.
Geller DS.
Clin Endocrinol (Oxf). 2005 May;62(5):513-20. doi: 10.1111/j.1365-2265.2005.02229.x.
Low-Renin Hypertension.
Athimulam S, Lazik N, Bancos I.
Endocrinol Metab Clin North Am. 2019 Dec;48(4):701-715. doi: 10.1016/j.ecl.2019.08.003. Epub 2019 Sep 25.
Vascular endothelial mineralocorticoid receptors and epithelial sodium channels in metabolic syndrome and related cardiovascular disease.
Jia G, Hill MA, Sowers JR.
J Mol Endocrinol. 2023 Sep 13;71(3):e230066. doi: 10.1530/JME-23-0066. Print 2023 Oct 1.
Mineralocorticoid resistance.
Zennaro MC.
Steroids. 1996 Apr;61(4):189-92. doi: 10.1016/0039-128x(96)00011-6.
Abiraterone-Induced Endocrinopathies.
Decamps S, Lis R, Ekanayake P.
JCEM Case Rep. 2023 Apr 13;1(2):luad039. doi: 10.1210/jcemcr/luad039. eCollection 2023 Mar.
Primary Generalized Glucocorticoid Resistance Syndrome.
Kino T, Nicolaides NC, Charmandari E, Chrousos GP.
2024 May 19. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–.
Hyperaldosteronism.
Dominguez A, Muppidi V, Leslie SW, Gupta S.
2024 Oct 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Glucocorticoid resistance.
van Rossum EFC, van den Akker ELT.
Endocr Dev. 2011;20:127-136. doi: 10.1159/000321234. Epub 2010 Dec 16.
Pseudohypoaldosteronism.
Riepe FG.
Endocr Dev. 2013;24:86-95. doi: 10.1159/000342508. Epub 2013 Feb 1.
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME.
Circ Res. 2015 Mar 13;116(6):991-1006. doi: 10.1161/CIRCRESAHA.116.305697.
